3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
243
Squamous Cell Carcinoma of Head and Neck
137
Melanoma
137
Parkinson Disease 4, Autosomal Dominant Lewy Body
119
Neoplasm Metastasis
105
Triple Negative Breast Neoplasms
96
Neoplasms
90
Lung Neoplasms
88
Breast Neoplasms
79
Colorectal Neoplasms
70
Carcinoma, Renal Cell
69
Head and Neck Neoplasms
59
Urinary Bladder Neoplasms
50
Stomach Neoplasms
48
Ovarian Neoplasms
46
Endometrial Neoplasms
45
Carcinoma, Transitional Cell
44
Carcinoma, Hepatocellular
35
Uterine Cervical Neoplasms
34
Pancreatic Neoplasms
34
Esophageal Neoplasms
27
Recurrence
25
Prostatic Neoplasms
25
Carcinoma, Squamous Cell
25
Carcinoma
25
Sarcoma
24
Brain Neoplasms
23
Glioblastoma
22
Hodgkin Disease
19
Cholangiocarcinoma
19
Interventions
fludarabine
5
Cyclophosphamide
5
fludarabine phosphate
4
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
Bendamustine Hydrochloride
2
AP 1903 reagent
2
pembrolizumab
1
isatuximab
1
ibrutinib
1
Lenalidomide
1
Dexamethasone
1
CLR1404
1
CA-4948
1
Bortezomib
1
Bone Marrow Transplantation
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immunoproliferative Disorders
×
pembrolizumab
×
1 year
×
Clear all
NCT03349450
2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2
Completed
25 enrolled
18 charts